
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Squalene epoxidase CRISPR Activation Plasmid (h) | sc-402870-ACT | 20 µg | $397.00 | |||
Squalene epoxidase CRISPR Activation Plasmid (h2) | sc-402870-ACT-2 | 20 µg | $397.00 |
SQLE encodes squalene epoxidase, a flavin-dependent monooxygenase that catalyzes the epoxidation of squalene to 2,3-oxidosqualene, a committed, rate-influencing step in sterol biosynthesis. This ER-associated enzyme helps control cholesterol and other sterol levels, linking SQLE activity to membrane composition, lipid raft dynamics, and steroidogenic precursor availability. SQLE is regulated by cellular lipid status and intersects with SREBP-driven metabolic programs that coordinate cholesterol homeostasis and broader lipid metabolism. Dysregulated SQLE expression has been associated with altered sterol flux and metabolic reprogramming observed across multiple disease-relevant contexts, including proliferative and inflammatory states.
Squalene epoxidase CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous SQLE expression without altering the underlying DNA sequence.
Squalene epoxidase CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the SQLE locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the SQLE transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Squalene epoxidase expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native SQLE locus and enabling the study of Squalene epoxidase-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Squalene epoxidase pathway restoration in tumor cells with silenced or reduced SQLE expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.